This Week in Virology (TWiV) episode 1287, released on January 11, 2026, delved into two significant areas of virological research:…
Read More
TWiV 1288: Clinical Update with Dr. Daniel Griffin
In a recent clinical update delivered by Dr. Daniel Griffin and Vincent Racaniello on the "This Week in Virology" (TWiV)…
Read More
TWiV 1289: Building a better hepatitis B trap
This installment of "This Week in Virology" (TWiV), episode 1289, delves into two significant advancements in virology: a groundbreaking discovery…
Read More
Talawar Therapeutics and JATT II Acquisition Complete Business Combination to Advance Novel Immunology Therapeutics
In a significant development poised to reshape the landscape of immunology therapeutics, New Jersey-based Talawar Therapeutics has officially merged with…
Read More
TWiV 1290: Clinical update with Dr. Daniel Griffin
In a comprehensive clinical update presented on the "This Week in Virology" (TWiV) podcast, Dr. Daniel Griffin, alongside host Vincent…
Read More
TWiV 1291: A Foot in the Door for Cytomegalovirus and a Neurovirulent Poliovirus Emergence in Uganda
This installment of "This Week in Virology" (TWiV) delves into two significant viral developments: the emergence of a neurovirulent double…
Read More
TWiV 1292: Clinical update with Dr. Daniel Griffin
In a stark assessment of the current state of public health in the United States, Dr. Daniel Griffin and Vincent…
Read More
The enemy of your parasite is your friend
On February 1, 2026, the podcast "This Week in Virology" (TWiV) episode 1293 delved into two significant scientific findings with…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
TWiV 1284: Clinical update with Dr. Daniel Griffin
In a post-New Year’s Eve recording, Dr. Daniel Griffin and Vincent Racaniello of "This Week in Virology" (TWiV) offered a…
Read MoreYOU MAY HAVE MISSED
